Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-06-23 04:47 | 2020-06-18 | RPRX | Royalty Pharma plc | Giuliani Mario Germano | Director, 10% owner | Pharmaceutical Preparations | BUY | $28.00 | 50,000 | $1,400,000 | 50,000 | +100.0% |
| 2020-06-23 00:31 | 2020-06-19 | AVEO | N/A | Sonsini Peter W. | 10% owner | Other | BUY | $5.25 | 1,428,571 | $7,499,998 | 3,952,958 | +56.6% |
| 2020-06-23 00:28 | 2020-06-19 | AVEO | N/A | Makhzoumi Mohamad | 10% owner | Other | BUY | $5.25 | 1,428,571 | $7,499,998 | 3,952,958 | +56.6% |
| 2020-06-23 00:27 | 2020-06-19 | AVEO | N/A | Florence Anthony A. Jr. | 10% owner | Other | BUY | $5.25 | 1,428,571 | $7,499,998 | 3,952,958 | +56.6% |
| 2020-06-23 00:26 | 2020-06-19 | AVEO | N/A | Growth Equity Opportunities Fund IV, LLC | 10% owner | Other | BUY | $5.25 | 1,428,571 | $7,499,998 | 3,952,958 | +56.6% |
| 2020-06-22 15:34 | 2020-06-17 | PHD | Pioneer Floating Rate Fund, Inc. | Saba Capital Management, L.P. | 10% owner | Other | BUY | $9.76 | 303,174 | $2,958,978 | 6,124,520 | +5.2% |
| 2020-06-23 00:26 | 2020-06-19 | AVEO | N/A | BASKETT FOREST | 10% owner | Other | BUY | $5.25 | 1,428,571 | $7,499,998 | 3,952,958 | +56.6% |
| 2020-06-23 00:30 | 2020-06-19 | AVEO | N/A | SANDELL SCOTT D | 10% owner | Other | BUY | $5.25 | 1,428,571 | $7,499,998 | 3,952,958 | +56.6% |
| 2020-06-23 00:29 | 2020-06-19 | AVEO | N/A | MAKOWER JOSHUA | 10% owner | Other | BUY | $5.25 | 1,428,571 | $7,499,998 | 3,952,958 | +56.6% |
| 2020-06-23 04:55 | 2020-06-18 | RPRX | Royalty Pharma plc | FORD WILLIAM E | Director | Pharmaceutical Preparations | BUY | $28.00 | 1,500,000 | $42,000,000 | 1,500,000 | +100.0% |
| 2020-06-23 00:31 | 2020-06-18 | RPRX | Royalty Pharma plc | ADAGE CAPITAL PARTNERS GP, L.L.C. | 10% owner | Pharmaceutical Preparations | BUY | $28.00 | 3,000,000 | $84,000,000 | 46,015,330 | +7.0% |
| 2020-06-23 01:06 | 2020-06-18 | GRPN | Groupon, Inc. | LEFKOFSKY ERIC P | Director, 10% owner | Services-Advertising Agencies | BUY | $21.57 | 250,000 | $5,391,550 | 34,134,994 | +0.7% |
| 2020-06-22 23:21 | 2020-06-18 | AXS | AXIS CAPITAL HOLDINGS LTD | DAVIS CHARLES A | Director | Fire, Marine & Casualty Insurance | BUY | $42.61 | 575,000 | $24,503,165 | 2,423,733 | +31.1% |
| 2020-06-23 02:52 | 2020-06-19 | IDYA | IDEAYA Biosciences, Inc. | BVF PARTNERS L P/IL | 10% owner | Pharmaceutical Preparations | BUY | $14.31 | 117,996 | $1,688,924 | 237,394 | +98.8% |
| 2020-06-22 20:33 | 2020-06-18 | BIF | SRH Total Return Fund, Inc. | COURTNEY M. CICIORA TRUST | 10% owner | Other | BUY | $9.54 | 223,419 | $2,130,300 | 1,150,096 | +24.1% |
| 2020-06-22 20:20 | 2020-06-18 | BIF | SRH Total Return Fund, Inc. | AMANDA N. CICIORA TRUST | 10% owner | Other | BUY | $9.54 | 223,419 | $2,130,300 | 1,150,096 | +24.1% |
| 2020-06-22 20:06 | 2020-06-18 | BIF | SRH Total Return Fund, Inc. | JACK S. CICIORA TRUST | 10% owner | Other | BUY | $9.54 | 223,419 | $2,130,300 | 1,150,096 | +24.1% |
| 2020-06-22 19:48 | 2020-06-18 | BIF | SRH Total Return Fund, Inc. | JOHN X. CICIORA TRUST | 10% owner | Other | BUY | $9.54 | 175,122 | $1,669,788 | 967,009 | +22.1% |
| 2020-06-19 23:35 | 2020-06-18 | CNA | CNA FINANCIAL CORP | LOEWS CORP | 10% owner | Fire, Marine & Casualty Insurance | BUY | $32.80 | 99,367 | $3,259,486 | 243,214,203 | +0.0% |
| 2020-06-19 01:02 | 2020-06-16 | GBIO | Generation Bio Co. | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% owner | Pharmaceutical Preparations | BUY | $19.00 | 1,100,000 | $20,900,000 | 2,112,546 | +108.6% |
| 2020-06-18 23:02 | 2020-06-16 | RNA | Avidity Biosciences, Inc. | Cormorant Asset Management, LP | Other | Pharmaceutical Preparations | BUY | $18.00 | 300,000 | $5,400,000 | 2,514,545 | +13.5% |
| 2020-06-19 00:29 | 2020-06-16 | GBIO | Generation Bio Co. | Casdin Capital, LLC | 10% owner | Pharmaceutical Preparations | BUY | $19.00 | 650,000 | $12,350,000 | 1,611,215 | +67.6% |
| 2020-06-18 23:47 | 2020-06-16 | LQDT | LIQUIDITY SERVICES INC | Angrick William P III | Director, Officer, 10% owner - Chairman of the Board and CEO | Services-Business Services, NEC | BUY | $6.02 | 182,160 | $1,096,476 | 5,334,307 | +3.5% |
| 2020-06-18 23:30 | 2020-06-16 | PCVX | Vaxcyte, Inc. | TPG Group Holdings (SBS) Advisors, Inc. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $16.00 | 937,500 | $15,000,000 | 5,156,553 | +22.2% |
| 2020-06-19 00:33 | 2020-06-16 | AXS | AXIS CAPITAL HOLDINGS LTD | DAVIS CHARLES A | Director | Fire, Marine & Casualty Insurance | BUY | $42.20 | 772,707 | $32,610,399 | 1,848,733 | +71.8% |
| 2020-06-19 01:01 | 2020-06-16 | GBIO | Generation Bio Co. | Invus Public Equities, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $19.00 | 800,000 | $15,200,000 | 2,814,191 | +39.7% |
| 2020-06-17 23:41 | 2020-06-15 | CNA | CNA FINANCIAL CORP | LOEWS CORP | 10% owner | Fire, Marine & Casualty Insurance | BUY | $32.49 | 161,305 | $5,241,558 | 243,114,836 | +0.1% |
| 2020-06-17 20:03 | 2020-06-15 | LCRDX | Lord Abbett Credit Opportunities Fund | Christina & Robert Dow Foundation | 10% owner | Other | BUY | $9.04 | 442,478 | $4,000,000 | 2,428,989 | +22.3% |
| 2020-06-17 16:53 | 2020-06-15 | CNNE | Cannae Holdings, Inc. | Cox Richard L. | Officer - Executive Vice President & CFO | Retail-Eating & Drinking Places | BUY | $37.50 | 26,667 | $1,000,013 | 141,884 | +23.1% |
| 2020-06-18 01:29 | 2020-06-15 | PLYA | N/A | Sagicor Financial Co Ltd. | 10% owner | Other | BUY | $3.97 | 1,500,000 | $5,951,400 | 21,500,000 | +7.5% |
| 2020-06-18 03:25 | 2020-06-11 | FATE | FATE THERAPEUTICS INC | Redmile Group, LLC | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $28.31 | 1,412,928 | $39,999,992 | 12,629,737 | +12.6% |
| 2020-06-17 16:51 | 2020-06-15 | CNNE | Cannae Holdings, Inc. | Massey Richard N | Director | Retail-Eating & Drinking Places | BUY | $37.50 | 26,667 | $1,000,013 | 260,566 | +11.4% |
| 2020-06-17 21:27 | 2020-06-15 | PHD | Pioneer Floating Rate Fund, Inc. | Saba Capital Management, L.P. | 10% owner | Other | BUY | $9.62 | 910,810 | $8,766,273 | 5,821,346 | +18.5% |
| 2020-06-17 23:59 | 2020-06-16 | GBIO | Generation Bio Co. | Seybold William | 10% owner, Other | Pharmaceutical Preparations | BUY | $19.00 | 400,000 | $7,600,000 | 1,918,819 | +26.3% |
| 2020-06-18 01:26 | 2020-06-15 | FOX | Fox Corp | MURDOCH LACHLAN K | Director, Officer - Executive Chairman, CEO | Television Broadcasting Stations | BUY | $28.29 | 101,556 | $2,873,019 | 252,928 | +67.1% |
| 2020-06-17 18:06 | 2020-06-15 | CNNE | Cannae Holdings, Inc. | MARTIRE FRANK R | Director | Retail-Eating & Drinking Places | BUY | $37.50 | 133,333 | $4,999,988 | 133,333 | +100.0% |
| 2020-06-17 16:54 | 2020-06-15 | CNNE | Cannae Holdings, Inc. | BICKETT BRENT B | Officer - President | Retail-Eating & Drinking Places | BUY | $37.50 | 26,667 | $1,000,013 | 417,716 | +6.8% |
| 2020-06-18 00:00 | 2020-06-16 | GBIO | Generation Bio Co. | Zone Healthcare Holdings, LLC | 10% owner, Other | Pharmaceutical Preparations | BUY | $19.00 | 400,000 | $7,600,000 | 1,918,819 | +26.3% |
| 2020-06-17 23:36 | 2020-06-15 | HCHC | INNOVATE Corp. | GLAZER AVRAM A | Director | Fabricated Structural Metal Products | BUY | $3.69 | 961,233 | $3,548,776 | 4,151,867 | +30.1% |
| 2020-06-17 02:21 | 2020-06-16 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Biological Products, (No Diagnostic Substances) | BUY | $16.00 | 93,000 | $1,488,000 | 2,222,967 | +4.4% |
| 2020-06-16 23:28 | 2020-06-16 | RNA | Avidity Biosciences, Inc. | RTW INVESTMENTS, LP | 10% owner | Pharmaceutical Preparations | BUY | $18.00 | 950,000 | $17,100,000 | 3,995,000 | +31.2% |
| 2020-06-17 02:13 | 2020-06-16 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Biological Products, (No Diagnostic Substances) | BUY | $16.00 | 250,000 | $4,000,000 | 2,309,554 | +12.1% |
| 2020-06-17 00:02 | 2020-06-15 | CI | Cigna Group | FOSS ERIC J | Director | Hospital & Medical Service Plans | BUY | $187.37 | 5,460 | $1,023,018 | 31,642 | +20.9% |
| 2020-06-17 00:29 | 2020-06-12 | BIF | SRH Total Return Fund, Inc. | COURTNEY M. CICIORA TRUST | 10% owner | Other | BUY | $9.57 | 223,419 | $2,137,159 | 1,150,096 | +24.1% |
| 2020-06-17 00:17 | 2020-06-12 | BIF | SRH Total Return Fund, Inc. | AMANDA N. CICIORA TRUST | 10% owner | Other | BUY | $9.57 | 223,419 | $2,137,159 | 1,150,096 | +24.1% |
| 2020-06-17 00:04 | 2020-06-12 | BIF | SRH Total Return Fund, Inc. | JACK S. CICIORA TRUST | 10% owner | Other | BUY | $9.57 | 223,419 | $2,137,159 | 1,150,096 | +24.1% |
| 2020-06-16 23:51 | 2020-06-12 | BIF | SRH Total Return Fund, Inc. | JOHN X. CICIORA TRUST | 10% owner | Other | BUY | $9.57 | 175,122 | $1,675,165 | 967,009 | +22.1% |
| 2020-06-16 22:32 | 2020-06-12 | AXDX | N/A | SCHULER JACK W | Director, 10% owner | Other | BUY | $9.34 | 134,080 | $1,252,307 | 16,508,032 | +0.8% |
| 2020-06-16 21:50 | 2020-06-16 | GBIO | Generation Bio Co. | Flynn James E | 10% owner, Other | Pharmaceutical Preparations | BUY | $19.00 | 225,000 | $4,275,000 | 1,186,215 | +23.4% |
| 2020-06-15 23:10 | 2020-06-11 | KZR | Kezar Life Sciences, Inc. | Equal Talent Investments Ltd | 10% owner | Pharmaceutical Preparations | BUY | $5.50 | 1,454,545 | $7,999,998 | 6,254,545 | +30.3% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.